Maybe I'll look everything over and post something
Post# of 36537
Emailed Joe with some comments, not the least of which was he should get his money back for the call. No question queue access and no operator available.
Nothing is really too much different than I thought, but I might just go away until the mouse testing results are in.
Terrible call all the way around. Content - too much science, not enough investor-related info, no IPO info after the first mention, no Excellagen timeline w VA, no update on NuGen Health (supposed to be receiving first revs around Thanksgiving); no access for callers; poor audio.
Same company as before the call, but anyone new who was listening knows very little about the good stuff.
Arg.
Try to salvage your Friday/weekend, everybody.